Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)

Hodi F. S.; Chiarion-Sileni V; Gonzalez R.

首页> 外文期刊>The lancet oncology >Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)

【24h】

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)

机译：单独在高级黑素瘤中单独服用Ipilimumab或Nivolumab（Checkmate 067）：多期，随机，第3阶段试验（Vol 19，PG 1480,2018）的4年结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第11期|共1页
作者
Hodi F. S.; Chiarion-Sileni V; Gonzalez R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018) [J] . Hodi F. S., Chiarion-Sileni V, Gonzalez R. The lancet oncology . 2018,第11期

机译：单独在高级黑素瘤中单独服用Ipilimumab或Nivolumab（Checkmate 067）：多期，随机，第3阶段试验（Vol 19，PG 1480,2018）的4年结果
2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018) [J] . Hodi F. S., Chiarion-Sileni V, Gonzalez R. The lancet oncology . 2018,第12期

机译：单独在高级黑素瘤中单独服用Ipilimumab或Nivolumab（Checkmate 067）：多期，随机，第3阶段试验（Vol 19，PG 1480,2018）的4年结果
3. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial [J] . Hodi Frank Stephen, Chiarion-Sileni Vanna, Gonzalez Rene, The lancet oncology . 2018,第11期

机译：单独在高级黑素瘤中单独服用Ipilimumab或Nivolumab（Checkmate 067）：多期，随机，第3阶段试验的4年结果
4. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial [O] . Laurence Albiges, Nizar M Tannir, Mauricio Burotto, 2020

机译：Nivolumab Plus IpiLimumab与unitinib进行先进的肾细胞癌的一线治疗：延长4年的第III期的后续行动214次试验
5. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [O] . Paul Baas, Arnaud Scherpereel, Anna K Nowak, 2021

机译：在不可切除的恶性胸膜间皮瘤（Checkmate 743）中，第一线Nivolumab加Ipilemimab：多期，随机，开放标签，第3阶段试验

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)

著录项

相似文献

相关主题

期刊订阅